Skip to content
July 01, 2022

Equity.Guru

Investment information for the new generation

BIOV.C

Closing the Diabetic Loop Before we get into this week’s sector roundup, let’s talk about diabetes. I am a sucker for sweets, so much so that I was diagnosed…
A Pain in the Behind   I don’t fear a lot of things. Well, other than spiders, heights, and being stabbed. However, more than anything I have always been afraid…
Old Memories I have always been a sucker for nostalgia. When I first started writing for Equity Guru, I spent most of my time covering biotechnology companies. Whether they…
BioVaxys Technology (BIOV.C) announced today that Immunologist Yvelise Barrios, MD, PhD, has joined the Company as a Scientific Adviser to support development of CoviDTH. Furthermore, studies conducted by Dr….
BioVaxys Technology (BIOV.C) announced today that the US Food and Drug Administration (FDA) has provided its official Written Response to the Company’s request for a Pre-IND Type B review…
In this show, Vancouver-based sportscast icon, Rob Fai, fills in for Jody Vance to talk to Biovaxys Founder and CEO, James Passin. They talk about Biovaxys’ journey before going…
BioVaxys Technology (BIOV.C) announced today that the US Food and Drug Administration (FDA) has reviewed its pre-IND request for a Type B review of the Company’s Covid-T™ program. Read…
BioVaxys Technology (BIOV.C) announced today that the US Food and Drug Administration (FDA) has reviewed its pre-IND request for a Type B review of the Company’s Covid-T™ program.   “We…
BioVaxys Technology (BIOV.C) announced today that it that it has initiated the clinical trials for Covid-T, the company’s diagnostic platform for detecting T-cell activity, according to a press release….